Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells

By Berg Maria   Lundqvist Andreas   McCoy Philip   Samsel Leigh   Fan Yong   Tawab Abdul   Childs Richard  

Cytotherapy, Vol. 11, Iss. 3, 2009-05 ,pp. : 341-355

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Ex-Vivo Expansion of CFU-GM and BFU-E in Unselected PBMC Cultures with Flt3L is Enhanced by Autologous Plasma

By Guo M   Miller W M   Papoutsakis E T   Patel S   James C   Goolsby C   Winter J N  

Cytotherapy, Vol. 1, Iss. 3, 1999-01 ,pp. : 183-194

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML

By Litzow Mr   Dietz Ab   Bulur Pa   Butler Gw   Gastineau Da   Hoering A   Fink Sr   Letendre L   Padley Dj   Paternoster Sf   Tefferi A   Vuk-Pavlović S  

Cytotherapy, Vol. 8, Iss. 3, 2006-05 ,pp. : 290-298

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Insufficient ex vivo expansion of Vα24+ natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14+ cells

By Imataki O.   Heike Y.   Makiyama H.   Iizuka A.   Ikarashi Y.   Ishida T.   Wakasugi H.   Takaue Y.  

Cytotherapy, Vol. 10, Iss. 5, 2008-01 ,pp. : 497-506

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Potent in vivo anti-tumor activity of isolated CD62L low lymph node cells sensitized in vivo with tumor lysate-pulsed DC-based vaccines

By Liu Z   Fan H   Wu Y   Chen B  

Cytotherapy, Vol. 7, Iss. 4, 2005-09 ,pp. : 353-362

Ashgate Publishing Ltd

Access to resources Recommend Favorite